Get the Stockscreener App
8.12
1.58%
-0.13
Newamsterdam Pharma Company N V stock is traded at $8.12, with a volume of 5,241.
It is down -1.58% in the last 24 hours and down -45.06% over the past month.
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
See More
Previous Close:
$8.25
Open:
$8.25
24h Volume:
5,241
Relative Volume:
0.82
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-19.15%
1M Performance:
-45.06%
6M Performance:
+35.33%
1Y Performance:
-8.35%
1-Day Range:
$7.51
$8.34
1-Week Range:
$7.51
$9.99
52-Week Range:
$5.52
$16.75
Newamsterdam Pharma Company N V Stock (NAMSW) Company Profile
Name
Newamsterdam Pharma Company N V
Sector
Industry
Phone
31 35 206 2971
Address
Gooimeer 2-35, Naarden
Compare NAMSW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAMSW
Newamsterdam Pharma Company N V
|
8.12 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.22 | 117.23B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
665.46 | 72.75B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
636.02 | 38.65B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.99 | 34.69B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.50 | 27.45B | 3.30B | -501.07M | 1.03B | -2.1146 |
Newamsterdam Pharma Company N V Stock (NAMSW) Latest News
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NAMS: Strategic Executive Compensation Plan Unveiled138K Shares at $21.36 - StockTitan
Where are the Opportunities in (NAMS) - Stock Traders Daily
Make Informed Decisions with NewAmsterdam Pharma Company NV (NAMS) Stock Updates - The News Heater
Ratios Uncovered: Breaking Down NewAmsterdam Pharma Company NV (NAMS)’s Trailing Twelve Months Metrics - The Dwinnex
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? - AOL
Results from NewAmsterdam Pharma Company NV (NAMS) show risk - US Post News
H.C. Wainwright initates NewAmsterdam Pharma Company NV (NAMS) rating to a Buy - Knox Daily
NewAmsterdam Pharma (NASDAQ:NAMS) Trading 4.1% HigherShould You Buy? - MarketBeat
China Universal Asset Management Co. Ltd. Makes New Investment in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
NAMSWNewAmsterdam Pharma Company N.V. Warrant Latest Stock News & Market Updates - StockTitan
JPMorgan Chase & Co. Increases Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by Moody Aldrich Partners LLC - MarketBeat
How To Trade (NAMSW) - Stock Traders Daily
Newamsterdam pharma CFO sells shares worth $1.5 million - MSN
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap DownTime to Sell? - MarketBeat
Newamsterdam pharma's COO sells $3.1 million in stock - MSN
Newamsterdam pharma CFO sells shares worth $1.5 million By Investing.com - Investing.com Australia
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Bought by JPMorgan Chase & Co. - Defense World
NewAmsterdam Pharma to Present at Guggenheim's SMID Cap Biotech Conference - The Manila Times
NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference - GlobeNewswire
NewAmsterdam Pharma's SWOT analysis: obicetrapib stock shows promise amid trials - MSN
Trend Tracker for (NAMS) - Stock Traders Daily
Royal Bank of Canada Reaffirms “Outperform” Rating for NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma's (NAMS) "Outperform" Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Deep Dive Into NewAmsterdam Pharma Stock: Analyst Perspectives (8 Ratings) - Benzinga
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Barclays PLC - Defense World
Analysts Set NewAmsterdam Pharma (NASDAQ:NAMS) Price Target at $39.80 - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Receives $39.80 Consensus Price Target from Analysts - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 4.9%What's Next? - MarketBeat
NewAmsterdam Pharma’s (NAMS) “Buy” Rating Reiterated at HC Wainwright - Defense World
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
14 Best 52-Week High Stocks To Buy According to Analysts - Insider Monkey
NewAmsterdam Pharma Company N.V. (NAMS): Analysts Recommend This 52-Week High Stocks Now - Insider Monkey
NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Buy" Rating from HC Wainwright - MarketBeat
NewAmsterdam Pharma Company N.V. Issues Press Release and Corporate PresentationOn January 10, 2025, NewAmsterdam Pharma Company N.V. filed a Form 8-K with the Securities and Exchange Commission, highlighting significant achievements in 2 - Defense World
NewAmsterdam gears up for obicetrapib regulatory filings By Investing.com - Investing.com Australia
NewAmsterdam gears up for obicetrapib regulatory filings - Investing.com India
NewAmsterdam Pharma Achieves Key Milestones in 2024 - TipRanks
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities - The Manila Times
NewAmsterdam's Cholesterol Drug Achieves Major Breakthroughs: 33% LDL-C Drop in Phase 3 Trials - StockTitan
Geode Capital Management LLC Purchases 1,399 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma Grants Equity Awards to New Chief People Officer, Key Hires - StockTitan
NewAmsterdam Pharma (NASDAQ:NAMS) Hits New 12-Month HighTime to Buy? - MarketBeat
Newamsterdam Pharma Company N V Stock (NAMSW) Financials Data
There is no financial data for Newamsterdam Pharma Company N V (NAMSW). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.27%
5.10%
Cap:
|
Volume (24h):